tiprankstipranks
Trending News
More News >
Pharmaron Beijing Co., Ltd. Class H (DE:17Q1)
FRANKFURT:17Q1
Germany Market

Pharmaron Beijing Co., Ltd. Class H (17Q1) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

17Q1 Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Pharmaron
Beijing Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

17Q1 Stock 12 Month Forecast

There Are No Analyst Ratings for DE:17Q1 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

17Q1 Financial Forecast

17Q1 Earnings Forecast

Next quarter’s earnings estimate for 17Q1 is €0.03 with a range of €0.03 to €0.04. The previous quarter’s EPS was €0.03. 17Q1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 17Q1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 17Q1 is €0.03 with a range of €0.03 to €0.04. The previous quarter’s EPS was €0.03. 17Q1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 17Q1 has Performed in-line its overall industry.

17Q1 Sales Forecast

Next quarter’s sales forecast for 17Q1 is €484.95M with a range of €484.95M to €484.95M. The previous quarter’s sales results were €430.78M. 17Q1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 17Q1 has Performed in-line its overall industry.
Next quarter’s sales forecast for 17Q1 is €484.95M with a range of €484.95M to €484.95M. The previous quarter’s sales results were €430.78M. 17Q1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 17Q1 has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CLSA Analyst forecast on DE:17Q1
Unknown Analyst
CLSA
Not Ranked
CLSA
€2.67€3.12
Buy
21.70%
Upside
Reiterated
10/30/25
Goldman Sachs Analyst forecast on DE:17Q1
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
€2.88€3.25
Buy
26.77%
Upside
Reiterated
10/30/25
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Goldman Sachs
Huatai Securities Analyst forecast on DE:17Q1
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
€3.09€3.64
Buy
42.37%
Upside
Reiterated
10/29/25
UBS Analyst forecast on DE:17Q1
Unknown Analyst
UBS
Not Ranked
UBS
€3.35€3.56
Buy
39.03%
Upside
Reiterated
10/28/25
HSBC
€3.04
Buy
18.74%
Upside
Reiterated
10/15/25
Citi
€3.57€4.22
Buy
64.81%
Upside
Reiterated
08/25/25
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Citi
Bank of China Analyst forecast on DE:17Q1
Unknown Analyst
Bank of China
Not Ranked
Bank of China
€2.7
Buy
5.64%
Upside
Reiterated
08/25/25
CICC Analyst forecast on DE:17Q1
Unknown Analyst
CICC
Not Ranked
CICC
€2.81
Buy
9.87%
Upside
Reiterated
08/22/25
Bank of America Securities Analyst forecast on DE:17Q1
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€2.52
Buy
-1.54%
Downside
Reiterated
08/22/25
Nomura Analyst forecast on DE:17Q1
Unknown Analyst
Nomura
Not Ranked
Nomura
€2.88
Buy
12.53%
Upside
Reiterated
08/21/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CLSA Analyst forecast on DE:17Q1
Unknown Analyst
CLSA
Not Ranked
CLSA
€2.67€3.12
Buy
21.70%
Upside
Reiterated
10/30/25
Goldman Sachs Analyst forecast on DE:17Q1
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
€2.88€3.25
Buy
26.77%
Upside
Reiterated
10/30/25
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Goldman Sachs
Huatai Securities Analyst forecast on DE:17Q1
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
€3.09€3.64
Buy
42.37%
Upside
Reiterated
10/29/25
UBS Analyst forecast on DE:17Q1
Unknown Analyst
UBS
Not Ranked
UBS
€3.35€3.56
Buy
39.03%
Upside
Reiterated
10/28/25
HSBC
€3.04
Buy
18.74%
Upside
Reiterated
10/15/25
Citi
€3.57€4.22
Buy
64.81%
Upside
Reiterated
08/25/25
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Citi
Bank of China Analyst forecast on DE:17Q1
Unknown Analyst
Bank of China
Not Ranked
Bank of China
€2.7
Buy
5.64%
Upside
Reiterated
08/25/25
CICC Analyst forecast on DE:17Q1
Unknown Analyst
CICC
Not Ranked
CICC
€2.81
Buy
9.87%
Upside
Reiterated
08/22/25
Bank of America Securities Analyst forecast on DE:17Q1
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€2.52
Buy
-1.54%
Downside
Reiterated
08/22/25
Nomura Analyst forecast on DE:17Q1
Unknown Analyst
Nomura
Not Ranked
Nomura
€2.88
Buy
12.53%
Upside
Reiterated
08/21/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharmaron Beijing Co., Ltd. Class H

3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+0.80%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +0.80% per trade.
1 Year
Success Rate
0/1 ratings generated profit
0%
Average Return
-10.70%
reiterated a buy rating 6 months ago
Copying Ruili Bian's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.70% per trade.
2 Years
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
-10.70%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -10.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

17Q1 Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Dec 25
Jan 26
Feb 26
Strong Buy
12
17
8
10
5
Buy
2
0
0
0
0
Hold
1
0
1
10
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
17
9
20
19
In the current month, 17Q1 has received 5 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 17Q1 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

17Q1 Stock Forecast FAQ

What is DE:17Q1’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:17Q1’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:17Q1, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Pharmaron Beijing Co., Ltd. Class H a Buy, Sell or Hold?
      Currently, no data Available
      What is Pharmaron Beijing Co., Ltd. Class H’s share price target?
      Currently, no data Available
      What do analysts say about Pharmaron Beijing Co., Ltd. Class H?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Pharmaron Beijing Co., Ltd. Class H?
      To buy shares of DE:17Q1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.